Skip to main content
OpenTrials
Completed

NCT Number: NCT05631639

Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor Capsule -A Pilot Study

This is a multi-center, prospective, non-randomized, open-label, exploratory clinical investigation performed to evaluate safety and effectiveness of the PillSense System when used for detection of blood in the stomach of patients suspected to have an Upper Gastrointestinal Bleed (UGIB).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Fakultní nemocnice Olomouc (FNOL), Olomouc, Czechia

Loading trial locations.

About this study

The PillSense System consists of the PillSense Capsule, an atraumatic, ingestible, and disposable capsule and PillSense Receiver, an external real-time monitor for results display. The PillSense Capsule is a non-invasive, single use device designed to detect blood in the stomach and wirelessly transmit the data to the external PillSense Receiver. The receiver is a handheld device which displays real-time information gathered from the capsule and clearly displays results, "Blood Detected" or "No Blood Detected".

All enrolled participants were admitted for suspected UGIB and were required to ingest a PillSense Capsule followed by esophagogastroduodenoscopy (EGD) within 1 hour of PillSense Capsule administration. All Patients underwent standard endoscopy following PillSense Capsule evaluation and results were compared with the PillSense System result, i.e., "Blood Detected" or "No Blood Detected".

The study was also designed to confirm transit of the PillSense Capsule through the GI tract and patient tolerability of the PillSense Capsule.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 -80 years
  • Ability to give written informed consent
  • Clinical suspicion of bleeding

Exclusion criteria

  • Circulatory or hemodynamic instability with a clear need for urgent endoscopy or surgery (systolic blood pressure <100 mmHg,heart rate > 100 / min)
  • Known current stenosis of the GI tract
  • Subject is using a pacemaker or other implantable electrical device
  • Dysphagia or difficulties in swallowing pills the size of the capsule
  • History of achalasia or known esophageal dysmotility
  • History of gastroparesis
  • History of severe constipation (1 bowel movement per week or less)
  • Patients who are currently pregnant or breastfeeding, or intend to become pregnant during the investigation
  • Presence of psychological issues preventing participation
  • Stomach bezoar
  • History of Crohn disease
  • History of diverticulitis
  • History of bowel obstruction
  • Suspected gastrointestinal tumor disease
  • Planned MRI investigation (MRI needed before the capsule is excreted)

Treatment and study plan

PillSense System

Device

The PillSense capsule is a diagnostic capsule equipped with a sensor for in vivo detection of liquid blood and a paired PillSense receiver for result display.

Primary outcomes

  1. Device feasibility

    Time frame: within 30 minutes

    Ability of PillSense Capsule to detect the presence or absence of blood and send the results to the PillSense receiver

Secondary outcomes

  1. Device sensitivity

    Time frame: within 2 hours

    Subjects with positive findings for blood based on PillSense and EGD

  2. Device Specificity

    Time frame: within 2 hours

    Subjects with negative findings for blood based on PillSense and EGD

  3. Safety

    Time frame: up to 3 weeks

    Number of patients that developed device-related adverse event (etc. retention, aspiration or bowel obstruction)

Sponsors and collaborators

Lead sponsor

EnteraSense Limited

Industry

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Nov 30, 2022
Registry last updated
Nov 30, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.